Immunicon's board of directors has elected Byron Hewett as president and chief operating officer, the company announced today.
Previously, Hewett was the company's COO and general manager of cancer products. Hewett joined Immunicon in October 2004 after spending 20 years in healthcare and life sciences management. He was senior vice president of sales and marketing and general manager for North America for Qiagen and vice-president of worldwide marketing for Bayer Diagnostics (previously Chiron Diagnostics).
He received his Master's degree in management from Northwestern University's J.L. Kellogg Graduate School of Management and a B.Sc. from the University of Virginia's McIntire School of Commerce.
The company also announced that its chief executive officer, Edward Erickson, will step down from his post on March 31, 2006. Erickson will remain chairman.
deCODE genetics announced Jean-Francois Formela has resigned from its board of directors, effective today.
Formela, a senior partner at Atlas Venture, has served on deCODE's board since the formation of the company in 1996. He resigned to devote his time to a new Atlas fund.
Atlas was a member of the group of venture firms that helped finance deCODE's start.
Kurt Petersen resigned from Cepheid's board of directors on Dec. 19, according to documents filed with the Securities Exchange Commission late last week. Petersen's resignation will be effective as of Dec. 31.
Currently the chief executive officer and a director of SiTime, Petersen co-founded Cepheid and served as president from August 1996 to August 2004. He was also the company's chief operating officer from 1996 to 2003 and the chief technical officer from 2003 to 2004. He has been a Cepheid director since August 1996.
Promoted? Changing jobs?GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.